Trials
4 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hemophilia A With Inhibitor, Hemophilia B With Inhibitor, Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor, Hemophilia A or B, Hemophilia a and B
- Main trialPhase 3
- “The purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B with inhibitors and is safe to use. Successfully screened participants will be randomly assigned to KN057 Prophylaxis (Arm 1) versus No Prophylaxis (Arm 2) at a ratio of 2:1. Participants in KN057 Prophylaxis will receive KN057 prophylaxis for 52 weeks upon enrollment. Participants in No Prophylaxis will first receive on-demand treatment for 26 weeks, then switch to KN057 prophylaxis for 26 weeks.The trial period is 59 weeks, including a 3-week screening period, a 26-week main trial, a…”In the company’s words, NCT06312475 on ClinicalTrials.gov
Other drugs for Hemophilia A With Inhibitor
- GS1191-0445Gritgen Therapeutics Co., Ltd. · Phase 3
- FRSW107Hangzhou Gensciences Biopharmaceutical Co., Ltd. · Phase 3
- SR604Shanghai RAAS Blood Products Co., Ltd. · Phase 3
- NXT007Roche · Phase 3
- DenecimigNovo Nordisk · Phase 3
- MarstacimabPfizer · Phase 3
Coming up1
- 30 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 15 Oct 2025 | Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors | |
| Phase 3Active, not recruiting | 15 Oct 2026 | Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors | |
| Phase 3Recruiting | 30 Dec 2027 | Safety of KN057 Prophylaxis in Patients With Haemophilia A or B | |
| Phase 2Not yet recruiting | 2 Sep 2026 | KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors | |
| Phase 2Completed | 17 Jan 2024 | KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026